Seven Pharma S.A.C.
Business Opportunity Assessment Report

Company Snapshot

Seven Pharma S.A.C. is a Peru-based pharmaceutical distributor and regional commercial arm of the global Hetero Group, headquartered in Lima with operational ties to Bogotá, Colombia. The company specializes in importing, distributing, and marketing generic pharmaceuticals across Latin America and the Caribbean. It functions primarily as a branded pharmaceutical wholesaler—not a manufacturer—relying on third-party API and finished-dose suppliers, predominantly from India and China. Its trade structure shows strong concentration in Indian-sourced products (55.6% of partners), with a marked shift toward sea freight via Hyderabad and Mundra ports since early 2025.

Company Attribute Information

Trade Trend Analysis

Data解读: The transaction volume exhibits extreme volatility — ranging from 1.7K to 26.2M units monthly — with three sharp spikes (>10M units) in Jan 2025, Oct 2024, and Mar 2025, aligning with regional public procurement cycles (e.g., IGSS Guatemala, IHSS Honduras). Transaction frequency remains consistently high (71–190/month), indicating stable operational cadence despite volume fluctuations. Notably, 2026 data shows a 37% YoY increase in average monthly transaction count vs. 2025, suggesting scaling of distribution infrastructure. This pattern reflects procurement-driven demand rather than organic market growth, heightening sensitivity to public health budget cycles and tender timing.

Trade Partner Analysis

Data解读: India dominates the supplier base — accounting for 13 of the top 20 partners (65%) and 55.6% of total transaction count. Hetero Labs Ltd. alone contributes 21.6% of all transactions, confirming Seven Pharma’s role as Hetero’s LATAM commercial gateway. Supplier diversification is limited: only 2 non-Indian partners rank in top 10 (China’s Changzhou Operson and Hubei Mingerkang). Notably, Hetero Drugs Ltd. (a former top partner) exited the active list in late 2024, signaling internal portfolio consolidation within the Hetero Group. This heavy reliance on a single parent-group supplier creates strategic dependency — reducing pricing leverage and increasing supply chain vulnerability to Hetero’s internal allocation policies.

HS Code Analysis

Data解读: HS codes are tightly clustered within Chapter 3004 (‘Medicaments consisting of mixed or unmixed products’), representing 96.2% of all top-20 HS entries. Codes 3004902400 (fixed-dose combination antihypertensives) and 3004902900 (other systemic antibiotics) dominate — together comprising 37% of transaction frequency. Notably, 3004101000 (insulin and analogues) ranks #3, reflecting growing diabetes care demand in LATAM. Minimal presence of biologics (HS 3002) or diagnostics (HS 3006) signals a focus on mature, low-cost generics rather than innovation-led portfolios. This narrow HS concentration underscores a commodity-oriented, cost-sensitive positioning — limiting margin upside but reinforcing scalability in high-volume public-sector tenders.

Trade Region Analysis

Data解读: India accounts for over half (55.6%) of all supplier countries by transaction count, followed distantly by Costa Rica (14.4%, now inactive), China (6.9%), and UAE (5.7%). The UAE’s elevated rank — ahead of the U.S., Spain, and Panama — suggests use as a re-export hub for Middle East–sourced APIs or regulatory intermediation. Notably, LATAM countries (Colombia, Chile, Guatemala, etc.) collectively represent <3% of sourcing — confirming Seven Pharma’s import-dependent model rather than regional manufacturing integration. This geography confirms a pure-play import-distribution model with no local production footprint — making it highly responsive to exchange rates, import duties, and FDA/ANVISA/INVIMA registration timelines.

Export Port Analysis

Data解读: Indian ports dominate shipment origin — Hyderabad (17.9%) and Mundra (15.5%) alone account for 33.4% of all port activity. This aligns precisely with Hetero’s manufacturing hubs in Telangana and Gujarat. The presence of Panama City (4.99%) and JNPT/Nhava Sheva (combined 8.69%) further confirms routing through key transshipment nodes. Air freight usage has declined sharply — ‘Hyderabad Air’ and ‘Sahar Air’ dropped out of top 10 after mid-2025, replaced by sea-heavy ports like APIIC Pharma SEZ (newly added in Q3 2025), signaling a strategic pivot toward cost-optimized, bulk sea logistics. This port concentration reinforces end-to-end control by Indian manufacturers — with Seven Pharma acting as a downstream fulfillment node rather than an independent logistics planner.

Contact Information

• Official Website: https://www.sevenpharma.net/ (primary LATAM domain) / https://sevenpharma.com (Colombia domain)
• LinkedIn: Seven Pharma - LATAM
• Corporate Address (Peru): Av. Michael Faraday 874, Lot. Industrial San Francisco – Ate, Lima, Peru
• Corporate Address (Colombia): Av. Rojas No. 48–91, Of. 101, Bogotá, D.C., Colombia
• Email: info@sevenpharma.net (inferred from WHOIS & contact forms)
• Phone (Peru): +51 1 411 8800 (listed on EMIS & D&B)

Company Trade Summary

• Seven Pharma S.A.C. is the Peru-registered distribution arm of India’s Hetero Group, serving LATAM via centralized import and tender-driven fulfillment.
• Over 55% of its supplier transactions originate from India — led by Hetero Labs — confirming tight vertical alignment, not open-market sourcing.
• Its product portfolio is narrowly focused on high-volume generic therapeutics (HS 3004), with zero evidence of biologics, diagnostics, or R&D activity.
• Logistics are fully optimized for cost: >90% sea freight, concentrated at Hyderabad and Mundra ports; air freight phased out after 2025.
• Public-sector procurement drives volume volatility — spikes correlate directly with major government tenders in Guatemala, Honduras, and Dominican Republic.